top of page
DISTINCTIVE
seconD- line folfiri aflIbercept in proSpecTIvely stratified, anti-egfr resistaNt, metastatic coloreCTal cancer patIents with ras validated wild typE status (distinctive)
AFLIBERCEPT POST ANTI-EGFR IN CCR
· Phase 2 study of second-line FOLFIRI-aflibercept in prospectively stratified, RAS wild type, anti-EGFR resistant, metastatic colorectal cancer patients: The DISTINCTIVE Trial
Scarica il file
bottom of page